PIRO Score for CAP

Why use it

CAP is the leading infectious cause of ICU admission and a major cause of sepsis-related mortality worldwide. PIRO stratifies ICU-admitted CAP patients into risk tiers, enabling decisions about monitoring intensity, empirical antibiotic breadth, early vasopressor use, and appropriate communication with families about prognosis. Its modular framework also identifies which domain is driving severity — host factors (P), pathogen virulence (I), inflammatory response (R), or established organ failure (O) — allowing targeted therapeutic focus.

About

The PIRO (Predisposition, Insult, Response, Organ dysfunction) score for community-acquired pneumonia (CAP) was developed by Rello and colleagues and published in Critical Care Medicine in 2009. Derived from the original sepsis staging framework proposed by Marshall et al. (2003), the PIRO model for CAP was adapted specifically to characterize severity in ICU-admitted pneumonia patients. Unlike PSI (Pneumonia Severity Index) or CURB-65, which focus on triage and hospital admission decisions, the PIRO score was designed for patients already requiring ICU-level care to predict in-hospital mortality and guide intensity of monitoring and treatment. The score integrates four conceptually distinct domains: (P) Predisposition — host comorbidities that increase susceptibility to severe outcomes; (I) Insult — characteristics of the infectious insult itself; (R) Response — the severity of the systemic inflammatory response; (O) Organ dysfunction — the number and severity of organ systems failing at presentation. Each component item is scored as 0 or 1 (present/absent), and the total score predicts ICU mortality with good discrimination (AUROC ~0.78–0.82 across validation cohorts). A validation study by Lisboa et al. (2009) confirmed the score's predictive accuracy in a separate cohort. The PIRO score complements APACHE II/III and PSI, offering a conceptually transparent, bedside-accessible tool for ICU prognostication in CAP.

When to use

• ICU-admitted patients with community-acquired pneumonia to predict in-hospital mortality
• Severity assessment at ICU admission to guide monitoring intensity and therapeutic aggressiveness
• Identifying patients who may benefit from early adjunctive therapies (corticosteroids, aggressive fluid resuscitation, early vasopressors)
• Prognostic communication with patients and families at ICU admission
• Serial reassessment during the ICU course to track trajectory and inform escalation or de-escalation decisions
• NOT designed as a pre-hospital or ED triage tool — use CURB-65, PSI, or SMART-COP for that purpose

Formula

Pearls & pitfalls

• The PIRO score was specifically validated for ICU-admitted CAP patients — it should NOT replace CURB-65 or PSI for triage decisions in the ED or ward.
• The "Insult" domain captures pathogen-related severity (multilobar involvement, high-risk pathogen) independently from host factors — this is clinically useful because a young patient with severe bilateral pneumonia (high I, low P) requires different management than an elderly patient with single-lobe pneumonia (high P, low I).
• A PIRO score ≥4 should trigger early discussion about care goals — in validation studies, in-hospital mortality exceeded 25% at this threshold.
• The PIRO framework explicitly separates organ failure (O) from the systemic response (R) — ensuring that patients with established multi-organ dysfunction are appropriately identified as very high risk even if their inflammatory response markers are normalizing.
• High-risk pathogens in the "Insult" domain include Pseudomonas aeruginosa, MRSA, Legionella, and multi-drug resistant organisms — empirical coverage should be broadened when these are suspected.
• Urea ≥11 mmol/L (BUN ≥31 mg/dL) in the Insult domain reflects both the severity of infection and renal involvement — an early marker of evolving multi-organ dysfunction.
• The systemic corticosteroid controversy in severe CAP: the CAPE COD trial (2023) showed hydrocortisone reduced 28-day mortality in severe CAP — consider for patients with PIRO ≥5 requiring vasopressors or with severe hypoxemia.
• The PIRO score was derived in a predominantly European ICU population — apply with appropriate caution in settings with very different pathogen epidemiology.
• Combining PIRO with biomarkers (procalcitonin, CRP, lactate) improves risk stratification beyond the clinical score alone.

Next steps

PIRO 0–2 (Low Risk): ICU mortality ~3–8%. Standard CAP management. Empirical antibiotics per ATS/IDSA guidelines (beta-lactam + macrolide or fluoroquinolone). Close monitoring. PIRO 3–4 (Moderate Risk): ICU mortality ~10–25%. Intensive monitoring. Ensure broad empirical antibiotic coverage. Obtain cultures before antibiotics. Monitor for organ dysfunction progression. PIRO 5–7 (High Risk): ICU mortality ~30–50%. Highest intensity monitoring. Vasopressors if shock. Consider systemic corticosteroids (methylprednisolone) if refractory shock or severe hypoxemia. Early bronchoscopy if clinical suspicion for unusual pathogen. Goals-of-care discussion. PIRO ≥8 (Very High Risk): ICU mortality >50%. Aggressive multimodal management. Goals-of-care and advance directive discussions early. Consider palliative care involvement.

Evidence

Rello J et al. A model for determining the outcomes of patients with community-acquired pneumonia. Crit Care Med. 2009;37(8):2466-2473. PMID:19531944. Derivation cohort n=529 ICU patients with CAP. AUROC 0.80. Lisboa T et al. External validation of the PIRO score for community-acquired pneumonia. Intensive Care Med. 2009;35(11):1862-1867. PMID:19636527. Validation cohort AUROC 0.79. Ruiz-Morales JM et al. Comparison of predictive models for sepsis and community-acquired pneumonia. Enferm Infecc Microbiol Clin. 2010. Evidence summary: PIRO outperforms APACHE II for mortality prediction in CAP-specific ICU populations in several studies.

References

1. Rello J et al. A model for determining the outcomes of patients with community-acquired pneumonia. Crit Care Med. 2009;37(8):2466-2473. — link
2. Lisboa T et al. External validation of the PIRO score for community-acquired pneumonia. Intensive Care Med. 2009;35(11):1862-1867. — link
3. Marshall JC et al. PIRO — a staging system for the twenty-first century. Crit Care Med. 2003;31(5):1560-1567. — link
4. Mandell LA et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-72. — link
5. Dequin PF et al. (CAPE COD Trial). Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med. 2023;388(21):1931-1941. — link